Governed Pipelines and the 90/10 Marketplace: DiagFlow's Double Moat

Two moats, one platform

DiagFlow — VisionLAB's governed, low-code platform for medical vision AI under BLUE LOTUS / Lotuschain.org — defends its position through two reinforcing structures: governance as architecture and marketplace network effects. Each makes the other stronger.

Moat one: governance you can verify

Healthcare buyers can't easily verify model provenance, version control, or training boundaries in most tools — and external LLM APIs threaten PHI leakage without strict controls. DiagFlow's answer is to make governance structural rather than contractual:

• Immutable pipeline graphs — every validated pipeline locks permanently once versioned: node attributes, runtime parameters, and internal models can't change, producing a forensic trail for clinical audit.
• Visible de-identification — DICOM tag scrubbing, burned-in annotation masking, and free-text redaction exist as explicit workflow nodes, not background promises.
• Fail-closed architecture — privacy anomalies halt execution and block API egress. The platform errs toward protecting data.
• Unalterable Model Cards — experimental and research models are blocked from live patient data, automatically.
• Automated Validation Package Generator — instant, standardized site benchmark cards for institutional review.

This is why we call it compliance as a product moat: deny-by-default access control, multi-tenant workspace isolation, TLS 1.3 in transit and AES-256 at rest are the baseline, and the audit story above is what hyper-regulated buyers actually choose.

Human review is the trust layer

Governance doesn't stop at data. No DiagFlow output — summary, report, or notification — is generated without crossing an un-bypassable Human Review and Override Interface. Machine findings arrive with Grad-CAM heatmaps mapping model logic onto the scan; the clinician must explicitly confirm, modify, or override. Every decision is written to an append-only audit log, and exports carry immutable watermarks linking pipeline version, model manifest IDs, and clinician approval. Human-to-AI diagnostic agreement is tracked continuously for drift detection.

Moat two: the Workflow Marketplace

Governance earns trust; the marketplace compounds it. Medical creators publish private, free, or paid workflow templates on DiagFlow's Workflow Marketplace — and for paid subscriptions, the creator retains 90% of gross intake while VisionLAB takes a 10% platform fee, covering orchestration, discovery, billing rails, privacy scanning, and compliant distribution.

The effect is structural: platform utility compounds across micro-clinical niches — radiology, digital pathology, ophthalmology, dermatology — without the core team growing proportionally. Every template a specialist publishes makes the platform more valuable to the next department, and the 90/10 split is the reason specialists choose to publish here rather than elsewhere.

Why the two reinforce each other

A marketplace only works when creators trust the distribution channel and buyers trust the goods. DiagFlow's immutable versioning means a purchased template is exactly what its author built — no silent mutation. The validation package generator means a hospital can benchmark a template against its own data before committing. Governance makes the marketplace trustworthy; the marketplace makes governance valuable at scale.

Commercial model, briefly

DiagFlow runs a tiered freemium-to-enterprise engine: free local WebGPU runs for individual researchers, per-seat Professional plans ($120/seat monthly or $1,200 annual) for hospital departments, pay-as-you-go compute for model builders, and annual Enterprise Healthcare contracts (from $150,000/yr) with private VPC deployment, BAA execution, SSO/RBAC, and SIEM audit exports. The beachhead is academic medical imaging AI labs and hospital innovation teams — data-rich, low-regulation, high-pain — expanding from there into departments and full hospital networks.

To pilot DiagFlow, publish on the marketplace, or partner on institutional validation, start a conversation with the VisionLAB team.